This trial is evaluating whether CART-TnMUC1 will improve 2 primary outcomes and 12 secondary outcomes in patients with Multiple Myeloma. Measurement will happen over the course of Up to 2 years.
This trial requires 112 total participants across 2 different treatment groups
This trial involves 2 different treatments. CART-TnMUC1 is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"A multidisciplinary approach to multiple myeloma treatment can result in improved patient outcomes and improved quality of life for patients with the disease and their family members." - Anonymous Online Contributor
"Multiple myeloma can affect any bone or muscle in the body, and can be deadly. The risk of multiple myeloma increases with age, smoking, and family history of multiple myeloma.\n" - Anonymous Online Contributor
"A number of inherited, environmental and biological factors may be involved in multiple myeloma. Genetic risk factors include the presence of certain inherited genes and chromosome translocations and deletions ("see" Multiple myeloma in the context of cancer genetics, section Multiple myeloma). The risk of developing multiple myeloma is also increased by exposure to ionizing radiation and certain agents, smoking, occupational exposure to benzene, asbestos and other occupational chemical toxins, and occupational exposures involving exposures to a mixture of carcinogens.\n" - Anonymous Online Contributor
"Significant weight loss and pain are common symptoms of MM. In the presence of severe disease, anemia and bone lesions, there is high suspicion for MM rather than other causes of weight loss or pain. Other signs of MM should be considered only after confirmation of clinical suspicion." - Anonymous Online Contributor
"2,700 of the 4,050 patients with multiple myeloma in the United States will develop or will die within five years of diagnosis. The median survival for multiple myeloma in the United States is seven years, and about 60% of patients live for more than five years. Most patients with multiple myeloma develop the disease before age 65, although 4% will develop age 85 or older." - Anonymous Online Contributor
"At diagnosis, patients with MM had a median lifespan similar to that of the general population. This result has implications for the design of trials that compare high-intensity therapies to treatment with standard-intensity therapy. Nevertheless, patients with MM may benefit from more intense therapy, even in the form of high-dose therapy." - Anonymous Online Contributor
"There have not been any new discoveries for treating multiple myeloma in the last five years. New research for treating multiple myeloma is usually focused on drug discovery. There are several types of drugs that are tested as treatments for multiple myeloma. These include bortezomib, lenalidomide, thalidomide, and immunomodulatory drugs." - Anonymous Online Contributor
"In the event of clinical trial enrollment, we believe that patients with myeloma who are eligible to participate in any of the currently available trials should be enrolled if the clinical trial does not involve intensive therapy or a drug that is not already approved. No other subset of patients should be excluded from clinical trials based on previous treatment." - Anonymous Online Contributor
"Cart-tnmuc1 was expressed on MM cells and its expression and secretion increased when cells were treated with CCL13, a chemokine important for MM cell survival. CCL13 decreased the viability of MM cells and induced apoptosis through the activation of caspases caspase 3, caspase 7 and caspase 8. These data suggest that cart-tnmuc1 may play a role in MM cell proliferation, survival and development, and the CCL13/cart-tnmuc1 axis may be a potential therapeutic target." - Anonymous Online Contributor
"Cart-TM improves physical and mental functioning by increasing functioning levels in MM patients. It will help MM patients return to normal life roles and may improve quality of life by decreasing physical and emotional burden, leading to enhanced QOL in daily medical management." - Anonymous Online Contributor
"The present study did not find a negative impact of carbetacin in patients with advanced MM, but it does show a strong antitumor effect in patients with RRMM. The potential of carbetacin deserves to be further investigated." - Anonymous Online Contributor
"Survival from MM was consistently worse in our institution than reported in the literature or for most other solid tumors. Patients were typically treated with relatively new agents and were treated after most patients with MM had succumbed to their disease. The reasons for the poor survival are likely multifactorial; patient, tumor, treatment, and institutional factors all contribute." - Anonymous Online Contributor